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BACKGROUND TO EURL ECVAM RECOMMENDATIONS 
The aim of a EURL ECVAM Recommendation is to provide EURL ECVAM views on the validity of 
the test method in question, to advise on possible regulatory applicability, limitations and 
proper scientific use of the test method, and to suggest possible follow-up activities in view of 
addressing knowledge gaps. 
During the development of its Recommendation, EURL ECVAM consults with its advisory body 
for Preliminary Assessment of Regulatory Relevance (PARERE) and its EURL ECVAM Stakeholder 
Forum (ESTAF). Moreover, EURL ECVAM consults with other Commission services and its 
international validation partner organisations of the International Cooperation on Alternative 
Test Methods (ICATM). Before finalising its recommendations, EURL ECVAM also invites 
comments from the general public and, if applicable, from the test method submitter. 
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EXECUTIVE SUMMARY 
 
EURL ECVAM fully endorses the ESAC opinion (Annex I) on the ECVAM-coordinated validation 
study of the Direct Peptide Reactivity Assay (DPRA) that assessed mainly protocol transferability 
and within- and between-laboratory reproducibility. The study was conducted in view of the 
DPRA's possible use as a component of an integrated approach for testing the potential of 
chemicals to cause skin sensitisation resulting in Allergic Contact Dermatitis (ACD). On the basis 
of the ESAC Opinion on the DPRA study, EURL ECVAM makes the following Recommendations: 
 
(1) Haptenation, i.e. the covalent binding of low-molecular weight substances ("haptens") to 
proteins present in skin is considered a prominent mechanism through which chemicals or 
their metabolites become antigenic. Haptenation has been described as a "molecular 
initiating event" in the OECD Adverse Outcome Pathway (AOP) for skin sensitisation which 
summarises the key events known to be involved in chemically-induced ACD (OECD, 2012). 
Therefore, information from peptide reactivity assays such as the DPRA is relevant for the 
assessment of the skin sensitisation potential of chemicals.  
(2) The EURL ECVAM study showed that the DPRA is transferable to suitably equipped 
laboratories that are proficient in high performance liquid chromatography (HPLC) analysis 
and the results obtained demonstrated within- and between-laboratory reproducibility of 
87% and 75%, respectively.  
(3) Full evaluation of the predictive capacity and applicability domain of the DPRA were outside 
the scope of the EURL ECVAM study. However, based on the study results and excluding 
metal compounds for which the test is not applicable, the accuracy of the DPRA for 
distinguishing sensitisers from non-sensitisers was 82% (sensitivity of 76%, specificity of 
92%) which is in agreement with published information from previous studies (Gerberick et 
al., 2007; Bauch et al., 2012; Natsch et al., 2013).  
(4) In addition to supporting identification of sensitisers/non-sensitisers, the DPRA may also be 
able to contribute to the assessment of sensitising potency, e.g. by supporting, within an 
integrated approach, the subcategorisation of sensitisers according to the United Nations 
Globally Harmonised System of Classification and Labelling of Chemicals (UN GHS; UN, 
2011). More work however is required to determine to which extent DPRA results relate to 
potency categories. 
(5) As the DPRA is an in chemico test method lacking metabolic capacity, substances that 
require metabolic (pro-haptens) or abiotic activation (pre-haptens) may not be detected by 
the DPRA. In addition, the DPRA specifically detects peptide reactivity associated with lysine 
and cysteine amino acids. These factors should be taken into account when considering 
negative results. 
(6) In view of the mechanistic complexity of skin sensitisation, DPRA data should always be 
considered in combination with other information in the context of integrated approaches 
such as Weight of Evidence (WoE) or Integrated Testing Strategies (ITS). Complementary 
information may be derived from test methods addressing other key events involved in skin 
sensitisation (OECD 2012) as well as non-testing methods including read-across information. 
Thus, EURL ECVAM recommends the development of integrated approaches for identifying 
and characterising skin sensitisation hazard (EURL ECVAM 2013) and potency. These 
approaches should be tailored to specific needs (e.g. depending on various sectorial and 
regulatory requirements). 
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(7) To support development of integrated approaches employing peptide reactivity assays 
(such as DPRA) and other sources of information, the applicability of the DPRA should be 
further characterised, e.g. through a retrospective analysis of existing data and, in case of 
identified data gaps, by generating additional information through targeted prospective 
testing. In particular, as pre-haptens are not consistently misclassified by the DPRA, the 
assay's applicability to these substances should be further investigated. Additionally, 
attention should be given to substances with electrophilic residues that react preferentially 
with amino acids other than cysteine or lysine. 
(8) Respecting the provision of Directive 2010/63/EU (EU, 2010) on the protection of animals 
used for scientific purposes, before embarking on animal experiments to identify substances 
with skin sensitisation potential, data from the DPRA test method should be considered in 
combination with complementary information in order to reduce and possibly avoid animal 
testing. In agreement with the provision of Annex XI point 1.2 of the REACH Regulation (EU, 
2006) data from non-standard testing methods, such as the DPRA, may be used to adapt the 
standard information requirements in the context of Weight of Evidence judgments. 
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1. Introduction 
1) The assessment of skin sensitisation potential is an important component in the safety 
evaluation of substances and represents a standard requirement of legislation on 
chemicals in the EU. These include: the Classification Labelling and Packaging of substances 
and mixtures (CLP) Regulation (EU, 2008a), the REACH Regulation (EU, 2006), the Plant 
Protection Products (PPP) Regulation (EU, 2009a), the Biocides Regulation (EU, 2012) and 
the Cosmetics Directive (EU, 2009b). As outlined in the EURL ECVAM Strategy for 
Replacement of Animal Testing for Skin Sensitisation Hazard Identification and 
Classification (EURL ECVAM, 2013), determining the skin sensitisation hazard properties of 
substances is a key requirement satisfying already the majority of regulatory needs, e.g. 
under the CLP and REACH Regulations in the EU. Other regulatory contexts can require an 
understanding of the relative potency of skin sensitisers with regard to both induction as 
well as elicitation of contact dermatitis in order to support a full risk assessment and 
appropriate risk management measures (e.g. setting of appropriate thresholds). 
2) Currently there are only in vivo regulatory accepted test methods to generate data 
satisfying regulatory requirements on skin sensitisation. For instance, in the frameworks of 
the Organisation for Economic Cooperation and Development (OECD) and the EU Test 
Methods Regulation (EU, 2008b), there are four accepted guidelines, describing: the 
Buehler Test and Guinea-pig Maximisation Test (GPMT), TG406 (OECD, 1992; EU test 
method B.6), the Local Lymph Node Assay (LLNA), TG429 (OECD, 2010a; EU test method 
B.42) and its non-radio-isotopic variants, the Local Lymph Node Assay: DA and the Local 
Lymph Node Assay: BrdU Elisa , TG 422A and TG 422B respectively (OECD, 2010b; OECD 
2010c). 
3) The key mechanistic events underpinning the skin sensitisation process that leads to 
Allergic Contact Dermatitis (ACD) in humans are well understood and have been recently 
summarised in the OECD report on “The Adverse Outcome Pathway (AOP) for Skin 
Sensitisation Initiated by Covalent Binding to Proteins“(OECD 2012). These include 1) the 
covalent binding of the chemical to the skin protein (haptenation), 2) events in 
keratinocytes including the production of danger signals and release of pro-inflammatory 
mediators 3) the maturation and mobilisation of dendritic cells (DC), the immuno-
competent cells in the skin, and 5) the antigen presentation to naïve T-cells and the 
proliferation of memory T-cells. Considerable progress has been made in recent years 
towards the development of alternative non-animal methods that address these key 
events. It is plausible that the initial event of haptenation is the major determinant of the 
skin sensitisation process and thus the protein-binding properties of a chemical should be 
intrinsically linked to its sensitisation potential and potency (Roberts & Aptula, 2008).  
4) There is general agreement within the scientific community that, in the near future, it is 
unlikely that one single alternative method will be able to provide sufficient information to 
replace the use of animals for this endpoint (Adler et al., 2011). Instead it is held that 
information from different alternative testing and non-testing methods used in 
combination will need to be integrated to address this health endpoint (Jowsey et al., 
2006; Adler et al., 2011). These methods should address different key events leading to 
skin sensitisation thus covering the mechanistic complexity of this endpoint. Nevertheless, 
it should not be ruled out a priori that skin sensitisation testing may, in the future, be 
addressed by one single test method. 
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5) EURL ECVAM coordinated a validation study of DPRA following a modular approach 
(Hartung et al., 2004) which had the following objectives: 
 To fully assess the reliability of the DPRA protocol, i.e. its transferability and within- 
and between-laboratory reproducibility.  
 To conduct a preliminary evaluation of the ability of the DPRA to discriminate skin 
sensitising from non-sensitising chemicals as defined by the Globally Harmonised 
System (GHS) for the classification and labelling of substances for skin sensitisation 
and as implemented in the European Union CLP Regulation concerning both 
substances and mixtures. Characterisation of preliminary predictive capacity was 
performed in view of determining the potential contribution of the method to 
contribute to decisions on hazard within integrated approaches. 
 To consider the ability of the DPRA to contribute to sub-categorisation of skin 
sensitising chemicals, e.g. into Sub-category 1A and Sub-category 1B as adopted in 
the 3rd revised version of the GHS. 
6) After completion of the study and finalisation of the Validation Study Report (EC-ECVAM-
2012), EURL ECVAM requested the ECVAM Scientific Advisory Committee (ESAC) to provide 
an ESAC Opinion on the study. An ESAC Working group (WG) was subsequently established 
which drafted an ESAC WG report, which then formed the basis of the ESAC Opinion (see 
annex) adopted by the ESAC on 17. 12. 2012. 
 
2. Test Method definition 
7) The correlation of protein reactivity with skin sensitisation potential is well recognised 
(Landsteiner and Jacobs, 1936; Dupuis & Benezra, 1982; Lepottevin et al., 1998). Chemical 
covalent binding to nucleophilic centres in skin proteins is regarded to be the molecular 
initiating event in the skin sensitisation AOP (OECD, 2012) without which skin sensitisation 
would not occur. Thus, chemicals capable of reacting with proteins either directly or after 
biotic or abiotic transformation may have the potential to act as a contact allergen. It 
should be noted that, in its current design, the DPRA does not provide a measure of 
reaction rate constant. 
8) The DPRA is an in chemico method which addresses peptide reactivity by measuring 
depletion of synthetic heptapeptides containing either cysteine or lysine following 24 
hours incubation with the test substance. Depletion of the peptide in the reaction mixture 
is measured by HPLC using UV detection. Average peptide depletion data for cysteine and 
lysine are then interpreted by using a classification model developed on the basis of a 
dataset of chemicals with known reactivity properties, in which chemicals are classified as 
having minimal, low, moderate or high reactivity. Substances with low to high reactivity are 
associated with substances that have skin sensitisation potential while those categorised as 
having minimal reactivity are considered to lack skin sensitisation potential. Due to the 
absence of a metabolic competent system in the assay, the DPRA is not suitable for the 
evaluation of pro-haptens, which require metabolic activation to act as sensitisers. The 
ability of the DPRA to detect pre-haptens, which require abiotic activation (e.g. through 
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oxidation by air), is not clear, although some pre-haptens are reported to be correctly 
identified by the DPRA. 
9) As a result of the ECVAM-coordinated study (EC EURL ECVAM, 2012), the standardised 
protocol was found to be transferable and reproducible within and between laboratories 
experienced in HPLC analysis. Some minor aspects of the protocol have been refined as a 
result of the experienced gained in the validation study. 
10) EURL ECVAM will publish in its DataBase service for ALternative Methods (DB-ALM, see 
http://ecvam-dbalm.jrc.ec.europa.eu), a comprehensive protocol including a detailed 
description of the test method and all necessary technical details needed by an end-user 
laboratory to implement it in a self-sufficient manner.  
 
3. Overall performance of the Direct Peptide Reactivity Assay 
 
Reference data  
 
A key criterion employed for selecting the validation test chemicals was availability of high 
quality in vivo testing data from the murine LLNA and the GPMT with concordant classification 
from these two assays. The set of chemicals used in the study consisted of one third of non-
sensitisers and two thirds of sensitisers with a balanced representation of potency classes 
(weak, moderate strong and extreme). Reference chemicals from the LLNA performance 
standards (OECD 2010a) were included in the chemical set. Additional details can be found in 
the Validation Study Report (EC EURL ECVAM, 2012). 
When interpreting the data of alternative methods, such as the DPRA, that have been largely 
developed and validated using animal reference data such as LLNA or GPMT the limitations of 
the reference data should be kept in mind. For instance, the predictive relevance of reference 
animal tests may not fully reflect the situation in the species of interest, i.e. humans. Notably, 
an evaluation of the LLNA in comparison to human data has shown an accuracy of about 72% 
(Anderson et al., 2011), i.e. there is a risk of false negative and false positive results. Moreover 
there is indication that the LLNA is deficient in detecting low to moderate sensitisers as well as 
metals and organometal compounds (EC, 2000). 
Transferability and Reproducibility 
11) On the basis of the results obtained during the study, it is evident that the DPRA can be 
readily transferred to new laboratories that are properly equipped and experienced with 
HPLC instruments and techniques.  
12) The assessment of the reproducibility was performed on the basis of concordance in 
classification (sensitiser/non-sensitiser). The experimental data generated in the study 
indicate that the within-laboratory reproducibility (ranging from 73% in the lead laboratory 
to 100% in one of the two naïve laboratory) and the between-laboratory reproducibility 
(75%) are acceptable for the proposed future use of the DPRA (i.e. in combination with 
other complementary methods).  
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Preliminary evaluation of predictive capacity based on the ring trial data 
13) Full evaluation of the predictive capacity of the DPRA was not within the scope of the EURL 
ECVAM study. However, the accuracy of the DPRA for dichotomous classification 
(sensitiser/non-sensitiser) on the basis of all 24 chemicals tested (including two metals, 
one pro-hapten, dihydroeugenol, and two pre-haptens, 4-phenylendiamine and R(+)-
Limonene), was 79% (sensitivity=71%, specificity=92%). When excluding the two metal 
compounds (which are considered outside the applicability domain and can be readily 
excluded from testing during practical application of the assay), the accuracy was 82% 
(76% sensitivity and 92% specificity). Thus, the predictive capacity determined in the study 
is consistent with published information from a larger set of data (Gerberick et al., 2007). 
Importantly, substances reported as false negatives in the EURL ECVAM study were 
generally substances with a low sensitisation potency in vivo.  
14) In relation to the ability of the DPRA to categorise substances in reactivity classes, data 
from the validation study does not support the use of the DPRA as a standalone method 
for potency categorisation. This is consistent with published information. However the 
study results indicate that the assignment of a chemical to a DPRA reactivity category may 
have the potential to contribute to the determination of its potency.  
 
4. Limitations 
 
4.1 Technical limitations 
 
15) Solubility of test substances: Peptide depletion values for substances with limited 
solubility in the solvents prescribed by the DPRA SOP cannot be derived with sufficient 
accuracy. Despite the fact that all the chemicals selected for the EURL ECVAM study were 
found to be compatible with the test system, limitations with the testing of insoluble 
chemicals have been reported in the submission to ECVAM. 
16) Co-elution: In those instances, mainly attributable to specific instrument settings, where 
the test substance or the reaction products elute at the same time as the peptide (co-
elution), an accurate measurement of peptide depletion cannot be made. The DPRA SOP 
provides instructions on how to approach different instances of co-elution, allowing in 
certain cases an estimation of the peptide depletion and reactivity class assignment. 
However there might be circumstances were this type of approximation is not appropriate. 
17) Cysteine dimerisation: Accurate determination of peptide depletion can also be hampered 
by substances promoting the oxidation of the thiol group in the cysteine peptide that leads 
to the formation of the cystine dimer. In such cases depletion of the peptide would be 
overestimated. 
4.2 Limitations with regard to applicability  
The following limitations of DPRA should be taken into consideration: 
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18) Restriction to lysine and cysteine: The DPRA is designed to measure reactivity of the 
electrophile towards two amino acids: the thiol group of cysteine and the primary amino 
groups of lysine. As other amino acids are not present in the assay, chemicals with 
preferential reactivity towards amino acids other than cysteine or lysine (e.g. nucleophilic 
sites in histidine), may lead to false negative results when tested in the DPRA. However, 
when considering this limitation, it should be also kept in mind that the relative 
percentages of substances reacting preferably with amino acids other than cysteine and 
lysine is at present unclear and that the cysteine and lysine peptides represent softer to 
harder model nucleophiles (OECD, 2012; Schwöbel et al., 2011) which would cover 
different reaction mechanisms   
19) Metal compounds: DPRA is not designed to accommodate the spectrum of reaction 
mechanisms considered to be associated with sensitising metals. For example Nickel, the 
most important metal allergen, is postulated to form coordination bonds with nucleophilic 
residues in histidine. However, metal compounds can be readily excluded from testing 
based on chemical structure and, therefore, this limitation can be easily addressed by 
simply avoiding the DPRA for the testing of metal compounds. 
20) Pro-haptens and pre-haptens: The DPRA is not designed to detect the sensitising 
properties of pro-haptens which require bioactivation, or pre-haptens which require 
abiotic transformation. Nevertheless, pre-haptens are in some cases reported to be 
correctly detected as sensitisers by the DPRA, as was the case in the EURL ECVAM study 
(n=2). However, the reasons why specific pre-haptens are detected while others are not 
remain unclear. To address the issue of pre- and pro-haptens, in silico expert systems such 
as TIMES-SS (Patlewicz et al., 2007; Roberts et al., 2007) and the OECD QSAR toolbox 
(www.qsartoolbox.org) could prove useful. Notably, a variation of the DPRA including an 
additional protocol step which mimics oxidative activation (co-incubation with horseradish 
peroxidase and hydrogen peroxide) to detect pre- and pro- haptens is under development. 
(Gerberick et al., 2009). 
21) Oxidation: Some substances that have oxidative properties (e.g. oxidative colourants) 
without necessarily causing haptenation may lead to possible false positive results when 
tested in the DPRA. 
 
5. Suggested regulatory use 
22) Due to the complexity of the mechanisms underlying skin sensitisation, it is likely that 
information from different methods (in silico, in chemico, in vitro) is needed to reduce or 
replace the need for animal testing, both for hazard identification and potency 
characterisation purposes. The DPRA is a reliable test method that provides information on 
peptide reactivity, which is considered to be the molecular initiating event of skin 
sensitisation (OECD 2012). Therefore, peptide depletion values generated with the DPRA 
could be used to support read-across from chemical analogues or combined with 
information from other non-animal methods in the context of a Weight of Evidence (WoE) 
approach or Integrated Testing Strategy (ITS). The extent of information needed to 
complement a DPRA result will depend on the intended application (e.g. hazard 
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identification, classification or potency assessment) and context (availability and quality of 
other information).  
23) For the purpose of hazard identification (i.e. identifying substances with sensitising 
potential), it is plausible that an unequivocal depletion value in the DPRA combined with 
the presence of a structural alert or positive QSAR prediction for skin sensitisation may 
prove sufficient for decision making, thus justifying the waiving of an animal test. To 
conclude on the absence of sensitising potential, additional information would be needed 
to increase confidence, such as in vitro data on downstream events. In any case a negative 
DPRA result should be interpreted with care, taking into consideration the possibility of 
false negatives due to (1) possible reactivity with amino acid residues other than cysteine 
and lysine, (2) the lack of metabolic capacity of the assay leading to possible 
misclassification of pro-haptens as well as (3) the uncertain capacity of the DPRA to 
correctly pick up pre-haptens. For hazard assessment purposes, possible uses of DPRA data 
in the context of a WoE or ITS have been reported in several scientific publications (Ball et 
al., 2011; Bauch et al., 2012). 
24) Use of results generated with the DPRA for potency prediction has also been proposed 
(Jaworska et al., 2011; Nukada et al., 2012). Results from the EURL ECVAM study showed 
that the limited number of substances with high DPRA reactivity fell into Category 1A of 
the UN GHS (UN, 2011), suggesting the potential application of DPRA results for potency 
sub-categorisation. However, further efforts are required to explore how DPRA data may 
support potency assessment, possibly in combination with data from other methods.  
25) When employed within an integrated approach, the DPRA may be useful to satisfy 
information requirements for Cosmetics (Regulation EC/1223/2009), Chemicals (Regulation 
EC/1907/2006), Biocides (EC/528/2012) and Plant Protection Products (Regulation 
EC/1107/2009).  
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6. Follow-up activities recommended by EURL ECVAM 
(1) In view of further testing with the DPRA, EURL ECVAM recommends that the revised 
protocol available at EURL ECVAM's DB-ALM service (http://ecvam-
dbalm.jrc.ec.europa.eu) be used. 
(2) The predictive capacity of the DPRA for assessing the sensitisation potential of substances 
should be further evaluated in the context of its use as part of integrated approaches to 
testing and assessment.  
(3) DPRA data should be analysed to understand the potential of the method to contribute to 
the potency assessment of substances, including sub-categorisation according to GHS (i.e. 
categories 1A and 1B). Use of existing human data and data from the LLNA are likely to be 
useful for this purpose. A study correlating DPRA data with potency categories derived 
from LLNA has recently been published (Natsch et al., 2013). 
(4) To support ITS development and to increase confidence in the DPRA method, additional 
prospective testing with the DPRA should be tailored towards better understanding of its 
applicability domain to better define how the method performs with (a) weak sensitisers, 
(b) pre-haptens and (c) chemicals that have selective reactivity towards amino acids other 
than cysteine and lysine. The reason for false positive predictions also deserves further 
investigation.  
(5) EURL ECVAM supports the development of an OECD Test Guideline for the DPRA. A 
project proposal has already been submitted to the OECD and included in the OECD 2012 
work program. As this test is best employed in combination with complementary 
methods, it should be considered in the current initiative being undertaken at OECD to 
develop a guidance document on Integrated Approaches for Testing and Assessment 
(IATA) for skin sensitisation.  
(6) EURL ECVAM recommends continued investment in the development of the next 
generation of peptide reactivity assays which can potentially address some of the 
limitations of the DPRA method. 
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Annex 1  ESAC Opinion 
 
Opinion of the EURL ECVAM Scientific Advisory Committee (EASC) on the 
ECVAM-led study of the Direct Peptide Reactivity Assay (DPRA) 
 
Ispra, 17 December 2012 
Summary of the ESAC Opinion 
The ESAC was asked to provide an opinion on an EURL-ECVAM led prevalidation study assessing 
the transferability and reproducibility (within- and between-laboratories) of the DPRA test 
method (primary objective of the study) in view of its possible future use as part of a non-
animal testing strategy for skin sensitization. The study had also been designed to provide 
preliminary information on a) the predictive capacity of the test method and b) its potential use 
for contributing to sub categorisation of sensitizing chemicals.  
The ESAC considered the scientific work presented of good quality. Overall, the conclusions 
made by the working group (WG) correspond well with the conclusions formulated in the report 
by the Validation Management Group (VMG).  
 
 The within laboratory reproducibility (WLR) of the test method with respect to 
concordance of classification (S/NS) was considered acceptable. 
 The data were considered strong enough to support transferability of the test to 
properly equipped, trained and staffed laboratories with the appropriate analytical 
capabilities.  
 The between laboratory reproducibility (BLR) of the test method with respect to 
concordance of classification was considered sufficient when compounds outside 
the applicability domain were excluded. 
 The preliminary predictive capacity as evaluated in this study is consistent with the 
published data (references 6, 7). 
 The potential for use of DPRA reactivity information in potency sub-categorisation 
requires further examination with a larger dataset. 
 
The ESAC had some questions about the statistical calculations underlying the determination of 
an adequate sample size to analyse reproducibility as a primary study goal.  The ESAC was 
concerned that possible limitations of the assay were not described in sufficient detail in the 
validation study report. 
The predictive capacity, applicability domain and limitations of the test are not defined yet, but 
the available data suggest that the test is a useful tool for early decision making during product 
development (screening) and a component in a weight-of-evidence (WoE) approach or 
integrated testing strategy (ITS).  
The ESAC recommends that the possible limitations of the DPRA should be further investigated 
specifically in relation to pre-/pro-haptens, either by additional prospective testing or through 
analysis of existing information as there may be a risk of false negative results associated with 
these chemicals. 
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1. Mandate of the ESAC 
The opinion of ESAC should support ECVAM with respect to the development of 
recommendations regarding the reliability (transferability, within and between laboratory 
reproducibility) of the DPRA and the potential regulatory use of the test method. 
(1) Study design – transferability, reliability and relevance  
 The ESAC was requested to review whether the prevalidation study was conducted 
appropriately in view of the objective of the study:  
 Reproducibility of the DPRA method within one laboratory (WLR); 
 Transferability to other laboratories; 
 Reproducibility in other laboratories (BLR); 
 Predictive capacity of the test method. 
 
 With respect to the design and conduct of the study, the following issues were to be 
addressed: 
 Clarity of the test definition (module 1)  
 Clarity of the definition of the study objective  
 Appropriateness of the study design in view of study objective 
 Appropriateness of the study execution: 
 Appropriateness of the statistical analysis used for analysing WLR, transferability, 
BLR and (preliminary) predictive capacity. 
(2) Conclusions of the study 
The ESAC was requested to assess the justification and plausibility of 
 Reproducibility (WLR and BLR) and transferability; 
 Preliminary predictive capacity; 
 Possible gaps between study design and study conclusions which remain to be 
addressed in view of the suggested conclusions/use; 
 Applicability and possible limitations of the test method, in particular in view of its 
potential use within an ITS for sensitisation. 
 
(3) Possible contribution of test method to integrated approach 
The ESAC is requested (a) to evaluate, on the basis of the data submitted in the validation study, 
the possible use of the test method (also within a strategy) to identify skin sensitisers, (b) to 
make additional recommendations (as required) on the proper scientific use of the test method 
within such a strategy taking specific aspects of this method into account (e.g. applicability, 
limitations etc.) and (c) to identify possible further information required (i.e. are there gaps) to 
be able to conclude on the plausibility of the suggested use (including within an ITS). 
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2. Detailed opinion of the ESAC 
The ESAC was asked to provide  an opinion on an EURL-ECVAM led study assessing the 
transferability and reproducibility (within- and between-laboratories) of the DPRA (primary 
objective of the study) in view of its possible future use as part of a non-animal testing strategy 
for skin sensitization. The study had also been designed to provide preliminary information on a) 
the predictive capacity of the test method and b) its potential use for contributing to sub-
categorisation of sensitizing chemicals.  
(1) Study design – transferability, reliability and relevance. 
The WLR was assessed at the level of concordance in prediction (S/NS). WLR for the three 
laboratories was in the range from 73% to 100% . The lowest value derived from the lead 
laboratory. The ESAC concluded that, in the context of the study, and in view of the fact that 
both naive laboratories exceeded the target of 85% as chosen by the VMG, the WLR was 
sufficient. 
 The definition of the reproducibility target (85%) was based upon i) the background 
and specific objectives of the validation study; ii) the standards of performance that 
can realistically be expected from an in vitro test and standards of performance 
which have been considered acceptable in previous validation studies; iii) the 
proposed used of the in vitro tests (i.e. as a partial replacement method to become 
part of a toolbox of tests to be used in combination); and iv) the power of the 
design of the validation study.  
 Transferability activities were divided into Training, Transferability and Qualification 
Runs The WLR was formulated for each partner to include 1) concordance in 
prediction, 2) depletion values for cysteine and lysine, as well as 3) control values. 
The data were considered strong enough to support transferability of the test to 
properly equipped, trained and staffed laboratories with the appropriate analytical 
capabilities.  
 During the transfer and blind testing phase one laboratory had difficulties in 
meeting the acceptance criteria defined in the SOP, due to the Reference Control C 
being marginally outside the acceptance criteria. The cause of the problem could 
not be identified. The ESAC recommends that these acceptance criteria should be 
re-examined. 
 The BLR was assessed in terms of 1) concordance in prediction and 2) depletion 
values for cysteine and lysine. Eighteen of the 24 chemicals were consistently 
classified (S/NS) by the three laboratories resulting in a BLR reproducibility of 75%, 
which is below the target (80%). The reproducibility assessment included 3 
chemicals (beryllium sulphate, nickel chloride and dihydroeugenol) that were 
considered by the VMG as outside the applicability domain of the test. The 
exclusion of these three substances considered to fall outside the applicability 
domain would lead to a BLR of 87.5%. For 15 out of the 24 chemicals the 
laboratories assigned the same reactivity class resulting in a BLR of 62.5%. Data 
variability was observed for results from chemicals with low or no reactivity.  
 The secondary goals included a preliminary evaluation of the ability of the test to 
discriminate skin sensitizers from non-sensitizers, and a preliminary consideration 
of the ability to contribute to sub-categorization of skin sensitising chemicals (GHS 
sub-category 1A and 1B). The validation study report (VSR) did not present a 
summary of the predictive capacity based on all 24 chemicals tested, since the VMG 
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judged three of them (beryllium sulphate, nickel chloride, dihydroeugenol) to fall 
outside the applicability domain. The two pre-haptens (4-phenylendeiamine and 
R(+)-Limonene) were included in the analysis as the VMG felt that there was 
insufficient evidence to exclude them from the evaluation of the predictive 
performance. The predictive capacity for all 24 substances was 77.8% (sensitivity: 
70.8%; specificity: 91,7%) while 82.4% (sensitivity: 73.5%; specificity: 91,7%) for the 
19 substances (since the WG felt that other two substances would fall outside the 
applicability domain, PPD and limonene).  
 The project was described and designed in clearly recognizable and well described 
phases including Test Definition (Module 1), Transferability (Module 3), Within 
Laboratory Reproducibility (WLR) (Module 2), Between Laboratory Reproducibility 
(BLR) (Module 4) and Predictive Capacity (Module 5).  
 Overall, the chosen statistical approach was considered appropriate. In the 
calculations of suitable sample size it was not clear for the ESAC why a power of 
75% was chosen for the BLR, especially as a more conventional 80% power was 
used for the WLR. However, since more chemicals than the minimum number were 
tested in both cases the actual power of the study was considered sufficient. 
 
(2) Conclusions of the study 
 Overall, the study design and the quality of the selected chemicals (N=24) were 
considered appropriate for the purpose of addressing the first objective of the 
study: Assessing the WLR and BLR of the DPRA.  
 Overall, the conclusions made by the WG correspond well with the conclusions 
drawn by the VMG as described in the VSR, indicating that these conclusions are 
supported by the results shown in the report.  
 The WLR of the test method with respect to concordance of classification (S/NS) 
met the target of 85% and was considered sufficient for the purpose of this 
study. 
 The data were considered strong enough to support transferability of the test to 
properly equipped, trained and staffed laboratories with the appropriate 
analytical capabilities.  
 In spite of a BLR (75%) below the target of 80%, the BLR of the test method with respect 
to concordance of classification was considered sufficient after the removal of the 
compounds outside the applicability domain. The potential for use of DPRA reactivity 
information in potency sub-categorisation requires further examination with a larger 
dataset. 
 The number of chemicals (N=24) did not provide support for a firm conclusion 
about the predictive capacity of the test method. The preliminary data were, 
however, considered promising. 
 The number of chemicals did not allow drawing a conclusion about the 
applicability domain of the test. Empirically the applicability domain seems to 
exclude pre-/pro-haptens and metal salts.  
 Chemicals that preferably react with amino acids other then cysteine and lysine 
may fall outside the applicability domain. In addition, some pre-/pro-haptens were 
reported as correctly identified. Finally, the data seem to indicate that the test 
method has problems identifying weak sensitizers. The uncertainty about the 
applicability domain may result in an unacceptable level of false negative results. 
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(3) Possible use of the test method within an integrated approach  
As outlined in the VSR and the ECVAM request for ESAC advice, the DPRA cannot be used as a 
stand-alone test method in a regulatory context but should be considered for use in an 
Integrated Testing Strategy (ITS). On the basis of the present report, especially negative 
outcomes have to be considered with care.  
 As pre-haptens are not consistently correctly predicted by the DPRA, there remains 
uncertainty about whether to consider pre-haptens as part of the applicability 
domain of the method or not.  
 Unless there are sufficiently accurate assays available identifying chemicals as pre-
/pro-haptens in view of excluding them from routine testing using the DPRA, such 
compounds will be tested in the DPRA and may cause false negative results.  
 The selection of cysteine and lysine-containing peptides selects for the majority, but 
not all, reactive chemicals.  
Regarding reactivity class, the data obtained did not support the possibility to use DPRA as a 
stand-alone test method for potency classification. This is in agreement with the statement of 
the VMG that the assay should be further evaluated for its capacity to "contribute" to a potency 
classification (VSR page 8). 
Information generated by the DPRA can be used to support regulatory decision making when 
used in the context of a weight-of-evidence approach or ITS. It is important to use the test in a 
context that allows confident conclusions about the protein-reactivity of the chemical, 
especially when the chemical in question is negative in the DPRA. As such the method may be 
helpful to address testing requirements of e.g. the REACH legislation and the 7th Amendment of 
the Cosmetic Directive. 
Its inclusion into future ITSs can be considered for the purpose of an eventual full replacement 
of current in vivo hazard identification assays. 
Recommendations: 
The DPRA addresses a key mechanism (haptenation) in the development of skin 
sensitization/allergic contact dermatitis. Overall the provided data support transferability and 
reproducibility of the test to qualified laboratories. The predictive capacity of the test is not 
defined yet, but the preliminary data profiles the test as a useful tool for early decision making 
during product development (screening) and a component in a weight-of-evidence approach or 
ITS for safety/hazard assessment. 
The ESAC recommends that the limitations of the DPRA (risk of false negative results) are 
further investigated specifically in relation to pre-/pro-haptens either by additional prospective 
testing or through analysis of existing information. 
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3. Informative background to the Mandate and Opinion 
Skin sensitizsation is the toxicological endpoint associated with substances that have the 
intrinsic ability to cause Allergic Contact Dermatitis, ACD in humans. ACD represents the most 
common manifestation of immunotoxicity in humans, i.e. adverse effects of xenobiotics 
involving the immune system. The identification of the skin sensitization potential represents 
an important component of the safety assessment of any new substance and especially for 
those intended for topical application (e.g. cosmetics). Current regulatory predictive tests for 
skin sensitization rely on the use of animals, these include: 
a) the traditional guinea pig tests: Buehler Test and Guinea-pig Maximisation Test (OECD 
TG 406, Ref.1),  
b) the Local Lymph Node Assay (LLNA, OECD TG 429, Ref.2) and its recently OECD adopted 
non-radioactive variants (OECD TG 422A, Ref.3 and OECD TG 422B, Ref.4).  
Despite the progress that has been made in the development of alternative methods for skin 
sensitisation hazard identification, there are currently no validated methods available. In 
addition none of the tests currently under development/evaluation is able to fully characterise 
the relative potency of sensitising substances and therefore, none of these assays is considered 
a stand-alone method, capable of fully replacing current animal procedures, in particular as 
regards to cosmetics.  
The current view therefore is to combine different test methods in order to address different 
key mechanisms of skin sensitisation: skin bioavailability, haptenation (the protein binding of 
chemicals which triggers immunological responses), epidermal inflammation, dendritic cell 
activation and migration, T cell proliferation. Test methods are currently under development 
which have been specifically designed to address these key mechanistic steps involved in skin 
sensitisation. Before these test methods can be routinely used, e.g. in ITSs, their capacity to 
produce reproducible results needs to be demonstrated as a first step.  
The Direct Peptide Reactivity Assay DPRA is addressing one of the key upstream events in the 
cascade of mechanisms leading to the induction of skin sensitisation. It measures the ability of 
chemicals to react with proteins (haptenation). There is good evidence that haptenation is a 
determinant step in the induction of skin sensitisation. Chemical allergens are usually low 
molecular weight chemicals which are not immunogenic per se. However, chemical allergens (or 
their metabolites, oxidation products) have electrophilic properties that allow them to bind 
covalently with the nucleophilic side chains of amino acids of skin proteins to form an 
immunogenic conjugate.  Already in 1936 this correlation between the reactivity of chemicals 
with proteins and their skin sensitisation potential was described (Landsteiner and Jacobs, 
Ref.5) and has in the meantime been extensively described in the literature. This knowledge is 
being exploited for the development of several in chemico reactivity assays with relevance for 
the testing of sensitisation potential, amongst these the DPRA assay.  
The DPRA is designed to screen the sensitisation potential of chemicals by measuring peptide 
depletion with UV-HPLC, following incubation of the test chemicals with synthetic 
heptapeptides containing either cysteine (peptide/chemical ratio in the reaction mixture 1:10) 
or lysine residues (peptide/chemical ratio in the reaction mixture 1:50) (Gerberick 2004, Ref.6). 
The average of peptide depletion values for cysteine and lysine are used to classify chemicals 
into four reactivity categories: minimal, low, moderate and high reactivity (Gerberick 2007, 
Ref.7). Based on the known correlation between haptenation/chemical reactivity and 
sensitisation potential, it is assumed that these reactivity classes as predicted by the DPRA may 
contribute to the characterisation of sensitiser potency.  
The possible predictive capacity of the DPRA is supported by the data of the original DPRA 
submission. On the basis of 133 chemicals, the DPRA classified chemicals as sensitisers or non-
sensitisers (in relation to LLNA data) with an accuracy of 86% (87% sensitivity, 83% specificity).   
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Annex 2  EURL ECVAM request for ESAC advice 
EURL ECVAM request for ESAC advice on an ECVAM-coordinated study 
concerning the transferability and reliability of the Direct Peptide 
Reactivity Assay (DPRA) for skin sensitisation testing 
 
1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
1) ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES 
If R1)applies please specify further: 
►Prevalidation Study YES 
At present (January 2012) ECVAM is conducting a 
study of three test methods for skin sensitisation 
testing: 1) the Direct Peptide Reactivity Assay 
(DPRA), 2) the human Cell Line Activation Test (h-
CLAT) and 3) the Myeloid U937 Skin Sensitisation 
Test (MUSST).  
The study assesses transferability and 
reproducibility of these test methods in view of 
their possible future use (e.g. as partial replacement 
methods) within an integrated approach for skin 
sensitisation hazard identification aiming at the full 
replacement of the currently used regulatory in vivo 
assays for this purpose. In addition the data 
generated in this study will inform possible future 
evaluations on the predictive capacity of these 
assays.  
While assessment of the h-CLAT and MUSST test 
methods are foreseen to be completed in 2012, the 
evaluation of the DPRA test method was finalised in 
2011 and the adopted Validation Study Report is 
foreseen to be available by January 2012. ESAC 
review will commence in February 2012 employing 
the same ESAC WG which is currently (January 
2012) peer reviewing the KeratioSens submission. 
Prospective Validation Study No 
Retrospective Validation Study No 
Validation Study based on Performance 
Standards 
No 
2) Scientific Advice on a test method submitted to ECVAM for 
validation  
(e.g. the test method's biological relevance etc.) 
No 
3) Other Scientific Advice  No  
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(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells etc.) 
 
2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE ESAC IS 
REQUESTED 
Prevalidation of the Direct Peptide Reactivity Assay (DPRA) for skin sensitisation testing 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
1) Background to skin sensitization and current predictive tests 
Skin sensitisation is the toxicological endpoint associated with substances that have the intrinsic 
ability to cause Allergic Contact Dermatitis, ACD in humans. ACD represents the most common 
manifestation of immunotoxicity in humans, i.e. adverse effects of xenobiotics involving the 
immune system. The identification of the skin sensitization potential represents an important 
component of the safety assessment of any new substance and especially for those intended for 
topical application (e.g. cosmetics). Current regulatory predictive tests for skin sensitization rely 
on the use of animals, these include: 
a) the traditional guinea pig tests: Buehler Test and Guinea-pig Maximisation Test (OECD 
TG 406, Ref.1),  
b) the Local Lymph Node Assay (LLNA, OECD TG 429, Ref.2) and its recently OECD adopted 
non-radioactive variants (OECD TG 422A, Ref.3 and OECD TG 422B, Ref.4).  
Despite the progress that has been made in the development of alternative methods for skin 
sensitisation hazard identification, there are currently no validated methods available. In 
addition none of the tests currently under development/evaluation is able to fully characterise 
the relative potency of sensitising substances and therefore, none of these assays is considered 
a stand-alone method, capable of fully replacing current animal procedures, in particular as 
regards to cosmetics.  
The current view therefore is to combine different test methods in order to address different 
key mechanisms of skin sensitisation: skin bioavailability, haptenation (the protein binding of 
chemicals which triggers immunological responses), epidermal inflammation, dendritic cell 
activation and migration, T cell proliferation. Test methods are currently under development 
which have been specifically designed to address these key mechanistic steps involved in skin 
sensitisation. Before these test methods can be routinely used, e.g. in integrated testing 
strategies, their capacity to produce reproducible results needs to be demonstrated as a first 
step.  
 
2) Background to the DPRA, h-CLAT, MUSST 
DPRA: 
The Direct Peptide Reactivity Assay DPRA is addressing one of the key upstream events in the 
cascade of mechanisms leading to the induction of skin sensitisation. It measures the ability of 
chemicals to react with proteins (haptenation). There is good evidence that haptenation is a 
determinant step in the induction of skin sensitisation. Chemical allergens are usually low 
molecular weight chemicals which are not immunogenic per se. However, chemical allergens (or 
their metabolites, oxidation products) have electrophilic properties that allow them to bind 
covalently with the nucleophilic side chains of amino acids of skin proteins to form an 
immunogenic conjugate.  Already in 1936 this correlation between the reactivity of chemicals 
with proteins and their skin sensitisation potential was described (Landsteiner and Jacobs, 
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Ref.5) and has in the meantime been extensively described in the literature. This knowledge is 
being exploited for the development of several in chemico reactivity assays with relevance for 
the testing of sensitisation potential, amongst these the DPRA assay.  
The DPRA is designed to screen the sensitisation potential of chemicals by measuring peptide 
depletion with UV-HPLC, following incubation of the test chemicals with synthetic 
heptapeptides containing either cysteine (peptide/chemical ratio in the reaction mixture 1:10) 
or lysine residues (peptide/chemical ratio in the reaction mixture 1:50) (Gerberick 2004, Ref.6).  
The average of peptide depletion values for cysteine and lysine are used to classify chemicals 
into four reactivity categories: minimal, low, moderate and high reactivity (Gerberick 2007, 
Ref.7). Based on the known correlation between haptenation/chemical reactivity and 
sensitisation potential, it is assumed that these reactivity classes as predicted by the DPRA may 
contribute to the characterisation of sensitiser potency.  
The possible predictive capacity of the DPRA is supported by the data of the original DPRA 
submission. On the basis of 133 chemicals, the DPRA classified chemicals as sensitisers or non-
sensitisers (in relation to LLNA data) with an accuracy of 86% (87% sensitivity, 83% specificity).   
h-CLAT & MUSST 
The h-CLAT and MUSST are based on the use of Dendritic Cell (DC)-like cell lines. Using flow 
cytometry, these test methods monitor the induction of cell surface markers associated with DC 
activation, following exposure to the chemical. In the MUSST, changes in CD86 expression in the 
U937 cell line are detected; in the h-CLAT modulation of both CD86 and CD54 expression are 
recorded in THP-1 cells. 
 
3) Study goals and design 
In the first quarter of 2009 the DPRA was formally submitted to ECVAM together with other two 
test methods namely the human Cell Line Activation Test (h-CLAT) and the Myeloid U937 Skin 
Sensitisation Test (MUSST), developed by companies associated with the European Cosmetics 
Association (Colipa) and optimized within Colipa ring trials. Following detailed scientific 
assessment of the information submitted, ECVAM judged the three methods to be mature 
enough to enter the ECVAM validation process.  
In September 2009 a formal study on the three above mentioned test methods was launched, 
with the main overall objective to evaluate their transferability and reliability (reproducibility 
within and between laboratories) when challenged with 24 coded chemicals.  
As a secondary goal of the study, the experimental data will be used to perform:  
a) A preliminary evaluation of the ability of each of the three tests to reliably discriminate skin 
sensitising (S) from non-sensitising (NS) chemicals as defined by the Globally Harmonised 
System (GHS, Ref. 6) for the classification and labelling of substances for skin sensitisation 
(category 1; no category) and as implemented in the European Commission Regulation (EC) No 
1272/2008 (Ref.8) on classification, labelling and packaging (CLP) of substances and mixtures.  
b) Where possible, a preliminary consideration of the ability of each of the three tests to 
contribute to sub-categorisation of skin sensitising chemicals, e.g. into Sub-category 1A (strong 
sensitisers) and Sub-category 1B (other sensitisers) as adopted in the 3rd revised version of the 
GHS. 
The study experimental design foresees the testing of the 24 coded test items in each of the 
three participating laboratories for the assessment of the between-laboratory reproducibility. A 
subset of 15 of these chemicals are being tested two additional times in each laboratory for the 
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evaluation of within-laboratory reproducibility. 
With respect to ECVAM's modular approach of validation (Hartung et al., 2004, Ref.10) the 
study will provide information on module 1) test definition, module 2) within laboratory 
reproducibility, module 3) transferability and module 4) between laboratory reproducibility. In 
addition, the data generated will provide preliminary information on module 5) predictive 
capacity; however, the number of chemicals tested is based on statistical considerations related 
to the evaluation of the reproducibility, and a larger sample size would be required for module 
5 to be considered fulfilled.  
References 
8. OECD, Organisation for Economic Cooperation and Development (1992) Skin 
Sensitisation Guidelines for Testing of Chemicals No. 406, Paris  
9. OECD, Organisation for Economic Cooperation and Development (2002) The Local 
Lymph Node Assay. Guidelines for Testing of Chemicals No. 429, Paris 
10. OECD, Organisation for Economic Cooperation and Development (2010a) Skin 
Sensitization: Local Lymph Node Assay: DA, Guidelines for Testing of Chemicals No. 
442A, Paris 
11. OECD, Organisation for Economic Cooperation and Development  (2010b) Skin 
Sensitization: Local Lymph Node Assay: BrdU-ELISA, Guidelines for Testing of Chemicals 
No. 442B, Paris 
12. Landsteiner K & Jacobs J (1936) Studies on the sensitisation of animals with simple 
chemical compounds. Journal of Experimental Medicine 64, 625-639 
13. Gerberick GF, Vassallo JD, Bailey RE, Chaney JG, Morrall SW, Lepoittevin JP, (2004)  
Development of a peptide reactivity assay for screening contact allergens. Toxicol Sci. 
81; 332-43. 
14. Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney JG, Lepoittevin JP, (2007). 
Quantification of chemical peptide reactivity for screening contact allergens: a 
classification tree model approach. Toxicol Sci. 97, 417-27. 
15. Anon. (2003). Globally Harmonised System of Classification and Labelling of Chemicals 
(GHS). Part 3: Health and Environmental Hazards, pp. 151-158. New York, NY, USA, and 
Geneva, Switzerland: United Nations Organisation. 
16. EU (2008b) Regulation (EC) No 1272/2008 (16 December 2008) of the European 
Parliament and of the Council on classification, labelling and packaging of substances 
and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and 
amending Regulation (EC) No 1907/2006. Official Journal of the European Union  L 353, 
(31/12/2008) p. 1-1355. 
17. Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, 
M., Hoffmann, S., Roi A.J., Prieto, P., Sabbioni, E., Scott, L., Worth, A. and  Zuang. V. 
(2004) A Modular Approach to the ECVAM Principles on Test Validity.  ATLA 32, 467-72. 
 
4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does ECVAM 
require advice on 
the current issue? 
The opinion of ESAC should support ECVAM with respect to the development of 
recommendations regarding the reliability (transferability, within and between 
laboratory reproducibility) of the DPRA and the potential regulatory use of the test 
method. 
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In addition the ESAC should advice with regard to the possible necessary further 
work required (in relation to predictive capacity, applicability, limitations of the 
test method) to assess the potential contribution of the DPRA to a future (not yet 
designed) testing strategy or test battery that would aim to achieve full 
replacement of the currently used animal tests for skin sensitisation hazard 
assessment. 
Moreover, based on the evaluation of the data submitted, the ESAC should 
provide advice on the potential usefulness of the DPRA test method within a 
testing strategy for skin sensitisation testing and the proper scientific use of the 
test method within such a testing strategy (e.g. with respect to its specific 
applicability and limitations). It is explicitly noted that the ESAC is not requested to 
suggest the precise placing of the submitted method in a hypothetical ITS, but 
rather to provide advice on the characteristics of the method relevant for its 
subsequent integration into an ITS at a later point in time (i.e. when other 
buildings blocks of such an ITS are known). 
 
4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
1) DESIGN & CONDUCT OF STUDY: The ESAC is requested to review whether the 
prevalidation study was conducted appropriately in view of the objective of the 
study. The study objective was to assess 
(1) the reproducibility of the DPRA method within one laboratory 
(2) its transferability to other laboratories  
(3) its reproducibility in other laboratories (BLR). 
(4) Furthermore, the study aimed at assessing, in a preliminary manner, the 
predictive capacity of the test method  
 
When reviewing the design and conduct of the study, the following issues should 
be addressed in particular: 
Clarity of the test definition (module 1)  
Clarity of the definition of the study objective  
Appropriateness of the study design in view of study objective, inter alia: 
Is the number of tested chemicals (24) sufficient for the purposes of the study? 
Are the reference data used for assessing in particular the predictive capacity 
appropriate and of good quality? 
Was the identification of chemicals conducted in an appropriate manner (i.e. 
presence or absence of selection criteria, justification etc.)? 
Is the adverse effect range of the selected chemicals appropriate for the purpose 
of the study 
In case of gaps (chemical class etc.) – are these justified? 
Is the number of laboratories sufficient? 
Appropriateness of the study execution (e.g. were there pre-defined acceptance 
criteria, were these respected? How were exceptions / deviations handled? Were 
provisions specified for retesting? Was the number of repetitions sufficient? etc.) 
Appropriateness of the statistical analysis used for analysing WLR, transferability, 
BLR and (preliminary) predictive capacity. 
2) CONCLUSIONS OF STUDY: The ESAC is requested to assess whether the 
conclusions, as presented in the Validation Study Report, are substantiated by the 
information generated in the study and are plausible with respect to existing 
information and current views (e.g. literature). 
In particular:  
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Are the conclusions on reproducibility (WLR and BLR) as well as transferability 
justified and plausible? 
Are the conclusions on preliminary predictive capacity justified and plausible with 
respect to existing information 
Are there possible gaps between study design and study conclusions which 
remain to be addressed in view of the suggested conclusions / use (see also point 
3)? 
 Do the data generated with this defined set of chemicals and available existing 
evidence provide sufficient information on applicability and possible limitations 
of the test method, in particular in view of its potential use within an ITS for 
sensitisation? 
 
3) SUGGESTED USE OF THE TEST METHOD: The ESAC is requested (a) to evaluate, 
on the basis of the data submitted in the validation study, the possible use of the 
test method (also within a strategy) to identify skin sensitisers, (b) to make 
additional recommendations (as required) on the proper scientific use of the test 
method within such a strategy taking specific aspects of this method into account 
(e.g. applicability, limitations etc.) and (c) to identify possible further information 
required (i.e. are there gaps) to be able to conclude on the plausibility of the 
suggested use (including within an ITS). 
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4.3  TIMELINES 
Timelines 
concerning this 
request 
When does 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: ESAC 37, 6/7 October 2012 or before 
through written procedure 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
YES, before ESAC 36 (20/21 March 
2012) 
Request to be presented to ESAC at 
ESAC plenary meeting 
NO 
 
5.  ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN ESAC 
5.1  ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to ECVAM? (YES/NO) 
1) ESAC Rapporteur  NO 
2) ESAC Working Group YES  
3) Invited Experts YES 
Ad 3): If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above (1-3):   
 
5.2  DELIVERABLES AS PROPOSED BY ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other than 
ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
NO 
D2 ESAC Peer Review Report 
and draft opinion 
YES 
If other than above (D1-D2): NO 
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6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
Count Description of document Available (YES/NO) File name 
1 OECD, Organisation for Economic 
Cooperation and Development 
(1992) Skin Sensitisation Guidelines 
for Testing of Chemicals No. 406, 
Paris  
YES ER2011-03_TG 406 
2 OECD, Organisation for Economic 
Cooperation and Development 
(2002) The Local Lymph Node Assay. 
Guidelines for Testing of Chemicals 
No. 429, Paris 
YES ER2011-03_TG 429 
3 OECD, Organisation for Economic 
Cooperation and Development 
(2010a) Skin Sensitization: Local 
Lymph Node Assay: DA, Guidelines 
for Testing of Chemicals No. 442A, 
Paris 
YES ER2011-03_TG 442A 
4 OECD, Organisation for Economic 
Cooperation and Development  
(2010b) Skin Sensitization: Local 
Lymph Node Assay: BrdU-ELISA, 
Guidelines for Testing of Chemicals 
No. 442B, Paris 
YES ER2011-03_TG 442B 
5 Gerberick GF, Vassallo JD, Bailey RE, 
Chaney JG, Morrall SW, Lepoittevin 
JP, (2004) Development of a peptide 
reactivity assay for screening contact 
allergens. Toxicol Sci. 81; 332-43. 
YES ER2011-03_scientific 
paper on DPRA 
6 Gerberick GF, Vassallo JD, Foertsch 
LM, Price BB, Chaney JG, Lepoittevin 
JP, (2007). Quantification of chemical 
peptide reactivity for screening 
contact allergens: a classification 
tree model approach. Toxicol Sci. 97, 
417-27. 
 
YES ER201-03_DPRA 
Classification Tree 
Model 
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7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
During its 34th meeting on March 22-23 the ESAC plenary unanimously decided to establish an 
ESAC Working Group Sensitisation charged with the detailed scientific review of four test 
methods for skin sensitisation. 
7.2 TITLE OF THE ESAC WORKING GROUP 
Full title:  
ESAC Working Group on Skin Sensitisation Test Methods 
Abbreviated title: 
ESAC WG Sensitisation 
 
7.3 MANDATE OF THE ESAC WG 
The EWG is requested to conduct a scientific review of the relevant studies concerning four skin 
sensitisation test methods (DPRA, MUSST, h-CLAT, Keratinosens). The review needs to address 
the questions put forward to ESAC by ECVAM. 
The review should focus on the appropriateness of design and conduct of the study in view of 
the study objective and should provide an appraisal to which extent the conclusions of the 
Validation Management Team (VMT) / test method submitter are substantiated by the 
information generated during the study and how the information generated relates to the 
scientific background available. 
 
7.4 DELIVERABLE OF THE ESAC WG 
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Secretariat a 
detailed ESAC Working Group Report outlining its analyses and conclusions. A reporting 
template has been appended (Appendix 1) intended to facilitate the drafting of the report. 
The conclusions drawn in the report should be based preferably on consensus. If no consensus 
can be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
The WG is further asked to prepare a draft ESAC opinion as basis for the discussions by the 
entire ESAC, which shall adopt its opinion to the extent possible by consensus and on the basis 
of the ESAC WG report as well as all documents that were made available to the WG as well as 
to all ESAC members. 
 
7.5 PROPOSED TIMELINES OF THE ESAC WG 
The following timelines have been proposed by ECVAM. These should be agreed upon during 
the face-to-face meeting (Item 1 in the table): 
Item Proposed date/time Action Deliverable 
1 1-3 February  Face to face meeting 1)Input on draft 
mandate 
2) Initial drafting of 
report 
2 20. / 21. March Progress report of WG Chair at 
ESAC36 
Presentation / oral 
summary 
3 14 May  Final report to be delivered to 
ESAC Coordinator/Secretariat. 
Final draft report 
4 8 June  Feedback from ESAC to WG on 
draft report (written procedure) 
Feedback on final draft 
report 
5 29 June  Final draft report available Final report 
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7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WG 
The ESAC WG is requested to address the three questions posed to the ESAC which have been 
broken down further in more specific questions by Secretariat (see section 4.2) and were 
discussed with the ESAC WG and approved by the ESAC. 
When preparing the final ESAC WG report to address these questions, the ESAC WG is 
requested to use a pre-defined reporting template. This template (see appendix 1) follows 
ECVAM's modular approach and addresses to which extent the standard information 
requirements have been addressed by the study. In addition, the template allows for addressing 
the specific questions outlined in section 4.2. The Secretariat will provide guidance if necessary. 
 
APPENDIX 1   REPORTING STRUCTURE FOR THE ESAC WG REPORT 
The following suggested structure follows the ECVAM information requirements ("modules") for 
scientific review following validation and allows at the same time for the description of the 
analysis and conclusions concerning more specific questions. A template has been created on 
the basis of the structure below and this template will be made available to the ESAC.  
The template can be used for various types of validation studies (e.g. prospective full studies, 
retrospective studies, performance-based studies and prevalidation studies). Depending on the 
study type and the objective of the study, not all sections may be applicable. However, for 
reasons of consistency and to clearly identify which information requirements have not been 
sufficiently addressed by a specific study, this template is uniformly used for the evaluation of 
validation studies. The current template is version 5. 
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Abstract 
 
Identification of the skin sensitisation hazard of chemicals has traditionally relied on the use of animals. Progress in the 
development of alternative methods has been prompted by the increasing knowledge of the key biological mechanisms 
underlying this human health effect, as documented by the OECD's recent report summarising the key biological events 
leading to skin sensitisation ("Adverse Outcome Pathway" (AOP) for skin sensitisation). The molecular initiating event 
defined within this AOP is the covalent binding of chemicals with skin proteins. Thus peptide reactivity assays may 
provide valuable information in the context of integrated approaches such as Weight of Evidence (WoE) or Integrated 
Testing Strategies (ITS) for skin sensitisation hazard and safety assessment. Based on these considerations, EURL ECVAM 
coordinated a validation study on the Direct Peptide Reactivity Assay (DPRA) addressing mainly the test method’s 
transferability and within- and between-laboratory reproducibility. Following independent scientific peer review by the 
EURL ECVAM’s Scientific Advisory Committee (ESAC) and having considered the input from regulators, stakeholders, 
international partners and the general public, EURL ECVAM concluded that the DPRA may prove a valuable component 
of a WoE or ITS for skin sensitisation hazard assessment. In addition to this, the DPRA may also be able to contribute to 
the assessment of sensitising potency, e.g. by supporting sub-categorisation of sensitisers according to UN GHS. 
However it is recognised that further efforts are required to explore how DPRA data may contribute to potency 
assessment.  
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As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide 
EU policies with independent, evidence-based scientific and technical support throughout the 
whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key societal 
challenges while stimulating innovation through developing new standards, methods and tools, 
and sharing and transferring its know-how to the Member States and international community. 
 
Key policy areas include: environment and climate change; energy and transport; agriculture 
and food security; health and consumer protection; information society and digital agenda; 
safety and security including nuclear; all supported through a cross-cutting and multi-
disciplinary approach. 
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